Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company.

This announcement is not for release, publication or distribution, in whole or in part, in or into any jurisdiction where to do so would constitute a violation of the applicable laws or regulations of such jurisdiction.

BioDlink International Company Limited
東曜藥業股份有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 1875)

CERTAIN UNAUDITED FINANCIAL INFORMATION FOR THE YEAR ENDED 31 DECEMBER 2025

This announcement is made by BioDlink International Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Pursuant to applicable disclosure requirements of the Taipei Exchange in Taiwan, Center Laboratories, Inc. (the Company's substantial shareholder holding over 20% of the Company's issued share capital, whose shares are listed on the Taipei Exchange in Taiwan) is required to disclose, on a date which is expected to be on or before 3 March 2026, certain unaudited consolidated financial information of the Group for the year ended 31 December 2025. Such date of disclosure is earlier than 18 March 2026, being the expected date of publication of the Company's 2025 annual results announcement containing the audited consolidated financial information of the Group for the year ended 31 December 2025.

In order to facilitate timely dissemination of information to investors and potential investors in Hong Kong and Taiwan, the Company's board of directors (the "**Board**") would like to inform the Company's shareholders and potential investors of the following unaudited consolidated financial information of the Group for the year ended 31 December 2025, which is extracted from the Group's latest unaudited management accounts and other information currently available.

Reference is made to the joint announcement dated 14 January 2026 issued by the Offeror, Wuxi Biologics and the Company in relation to, among others, the Offers (the "**Announcement**") and the composite document jointly issued by the Company and the Offeror dated 12 February 2026 in connection with the Offers (the "**Composite Document**"). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as defined in the Announcement and the Composite Document.

The unaudited consolidated financial information included in this announcement (the "**2025 Unaudited Annual Financial Information**") constitutes a profit forecast under Rule 10 of the Takeovers Code and would need to be reported on by the Company's financial advisers and auditors in accordance with Rules 10.4 and 10.9 of the Takeovers Code. The Company has applied for and the Executive of the SFC has granted a waiver in relation to the reporting on requirement under Rules 10.4 and 10.9 of the Takeovers Code in relation to the publication of the 2025 Unaudited Annual Financial Information. Accordingly, the 2025 Unaudited Annual Financial Information does not meet the standard required by Rule 10 of the Takeovers Code. The Independent Financial Adviser has confirmed that the 2025 Unaudited Annual Financial Information does not affect its opinion as set out in the Letter of the Independent Financial Adviser contained in the Composite Document.

IMPORTANT

As mentioned above, the Group's results for the year ended 31 December 2025 set out in this announcement are unaudited. The Group's results of operations in the past have fluctuated and may in the future continue to fluctuate from one period to another period. Accordingly, the Group's results of operations for any period should not be considered to be indicative of the results to be expected for any future period. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the securities of the Company.

Shareholders, RSA Holders, Option Holders and potential investors of the Company are advised to exercise caution when placing reliance on the 2025 Unaudited Annual Financial Information in assessing the merits and demerits of the Offers and when dealing in the securities of the Company.

Persons who are in doubt as to the action they should take should consult a licensed securities dealer or registered institution in securities, bank manager, solicitor, professional accountant or other professional advisers.

CONDENSED CONSOLIDATED BALANCE SHEET

	As at 31 December 2025 *RMB'000* **(unaudited)**	As at 31 December 2024 *RMB'000* (audited)
Current assets	**560,916**	743,277
Non-current assets	**698,373**	765,495
Current liabilities	**(273,515)**	(415,363)
Non-current liabilities	**(359,959)**	(363,754)
Total net assets	**625,815**	729,655

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE (LOSS)/ INCOME

	For the year ended 31 December 2025 ***RMB'000*** **(unaudited)**	For the year ended 31 December 2024 *RMB'000* (audited)
Revenue	**747,645**	1,098,329
Net (loss)/profit	**(100,369)**	34,757
Net (loss)/profit for the year and attributable to the equity holders of the Company	**(100,369)**	34,757
Other comprehensive (loss)/income	**(1,386)**	2,199
Total comprehensive (loss)/income for the year	**(101,755)**	36,956

The above information is subject to possible adjustments following further internal review and external audit, and is not based on any figure(s) or information which has/have been reviewed by the Company's external auditor or the Audit and Connected Transactions Review Committee. As mentioned above, the Company's 2025 annual results announcement containing the audited consolidated financial information of the Group for the year ended 31 December 2025 is expected to be published on 18 March 2026.

By order of the Board
BioDlink International Company Limited
Mr. Fu, Shan
Executive Director

Hong Kong, 3 March 2026

As at the date of this announcement, the executive director of the Company is Mr. Fu, Shan; the non-executive director of the Company is Dr. Liu, Weidong; and the independent non-executive directors of the Company are Ms. Sun, Hui, Mr. Zhang, Qing and Dr. Gu, Xuelin.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.

This announcement is published in English and in Chinese. In case of any inconsistency between the English version and the Chinese version, the English version prevails.